Lookup NU author(s): Dr Samuel Moses
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Hepatitis B virus (HBV) is a partially double stranded DNA virus that can integrate into host cell chromosomes as covalently closed circular DNA forms. HBV reactivation following hematopoietic stem cell transplantation in recipients with evidence of past HBV exposure, as well as exacerbation of a current HBV infection in HBV carrier recipients, secondary to chemotherapy and post-transplant immunosuppression that affect both humoral and cell-mediated control of HBV infection, are well documented in the literature. Management options include HBV-DNA screening and antiviral prophylaxis. Nucleos(t)ide analogues have been used at the start of chemotherapy and pretransplantation, with the course continuing for 6 months. However, depending on the serum HBV-DNA level, the antiviral agent might be given until a therapeutic end point is reached.
Author(s): Moses SE, Lim Z, Zuckerman MA
Publication type: Review
Publication status: Published
Journal: Expert Review of Anti-infective Therapy
Print publication date: 01/10/2011
ISSN (print): 1478-7210
ISSN (electronic): 1744-8336
PubMed id: 21973301